Equities analysts forecast that Abbott Laboratories (NYSE:ABT) will report sales of $7.76 billion for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Abbott Laboratories’ earnings, with the lowest sales estimate coming in at $7.73 billion and the highest estimate coming in at $7.77 billion. Abbott Laboratories posted sales of $6.64 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 16.9%. The firm is scheduled to issue its next earnings results on Thursday, July 19th.
According to Zacks, analysts expect that Abbott Laboratories will report full-year sales of $31.08 billion for the current fiscal year, with estimates ranging from $30.91 billion to $31.20 billion. For the next financial year, analysts forecast that the company will post sales of $32.97 billion per share, with estimates ranging from $32.66 billion to $33.27 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that cover Abbott Laboratories.
Top 10 Growth Stocks For 2019: Nordstrom Inc.(JWN)
Advisors' Opinion:- [By Trey Thoelcke]
And Nordstrom Inc. (NYSE: JWN) EPS are expected to grow 12.2% in the next five years, a turnaround from the 4.4% decline in the prior five years. However, recent sales projections for the next five years may tell another story. The share price is more than 5% higher than at the beginning of the year. The company is expected to release its second-quarter results later today.
- [By Chris Lange]
Nordstrom Inc. (NYSE: JWN) is scheduled to release its most recent quarterly results after the markets close on Thursday. The consensus estimates call for $0.44 in earnings per share (EPS) on $3.46 billion in revenue. The fiscal first quarter of last year reportedly had EPS of $0.37 and $3.35 billion in revenue.
- [By ]
On Thursday, earnings are expected from JCPenney Co. (JCP) , Action Alerts PLUS holding Nordstrom Inc. (JWN) , Nintendo Co. (NTDOY) and Walmart Inc. (WMT) .
Top 10 Growth Stocks For 2019: MEDIFAST INC(MED)
Advisors' Opinion:- [By Joseph Griffin]
MediBloc (CURRENCY:MED) traded 6.8% lower against the dollar during the 1-day period ending at 15:00 PM Eastern on May 27th. MediBloc has a total market cap of $73.40 million and $743,880.00 worth of MediBloc was traded on exchanges in the last 24 hours. One MediBloc token can currently be purchased for approximately $0.0247 or 0.00000339 BTC on major cryptocurrency exchanges including Bibox, Gate.io and Coinrail. During the last seven days, MediBloc has traded 8.3% higher against the dollar.
- [By Joseph Griffin]
MediBloc [QRC] (MED) is a proof-of-work (PoW) token that uses the HybridScryptHash256 hashing algorithm. Its genesis date was January 3rd, 2014. MediBloc [QRC]’s total supply is 4,097,545,844 tokens and its circulating supply is 2,966,384,100 tokens. The official website for MediBloc [QRC] is medibloc.org/en. MediBloc [QRC]’s official Twitter account is @MEDDevTeam. The Reddit community for MediBloc [QRC] is /r/MediBloc and the currency’s Github account can be viewed here. The official message board for MediBloc [QRC] is medium.com/@MediBloc.
- [By Logan Wallace]
MediBloc [QRC20] (MED) is a proof-of-work (PoW) token that uses the HybridScryptHash256 hashing algorithm. It was first traded on January 3rd, 2014. MediBloc [QRC20]’s total supply is 4,097,545,844 tokens and its circulating supply is 2,966,384,100 tokens. MediBloc [QRC20]’s official website is medibloc.org/en. MediBloc [QRC20]’s official Twitter account is @MEDDevTeam. The official message board for MediBloc [QRC20] is medium.com/@MediBloc. The Reddit community for MediBloc [QRC20] is /r/MediBloc and the currency’s Github account can be viewed here.
Top 10 Growth Stocks For 2019: Buffalo Wild Wings Inc.(BWLD)
Advisors' Opinion:- [By Steve Symington]
That's not to say it was a quiet day for every stock on the market. With earnings season ramping up, brewing giant Anheuser-Busch InBev (NYSE:BUD) and restaurant chain Buffalo Wild Wings (NASDAQ:BWLD) served as an exercise in contrast as investors reacted to their respective quarterly reports.
- [By Peter Graham]
A long term performance chart shows Dave & Busters Entertainment tripling in value before falling back while small cap upscale gentlemen's clubs and restaurant owner RCI Hospitality Holdings, Inc (NASDAQ: RICK) began taking off in 2016 and small cap Buffalo Wild Wings (NASDAQ: BWLD) is being acquired by Arby's Restaurant Group:
Top 10 Growth Stocks For 2019: Intuitive Surgical Inc.(ISRG)
Advisors' Opinion:- [By Motley Fool Staff]
In this segment from MarketFoolery, host Chris Hill and Motley Fool Asset Management's Bill Barker consider the case for healthcare innovator Intuitive Surgical (NASDAQ:ISRG), which has been on a tear for the past few years. Its pricey robots are growing ever more common and popular with hospitals and doctors, and based on the reaction of the market, investors must expect its current sales growth pace to continue.
- [By Stephan Byrd]
Traders sold shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) on strength during trading on Monday. $62.49 million flowed into the stock on the tick-up and $93.11 million flowed out of the stock on the tick-down, for a money net flow of $30.62 million out of the stock. Of all stocks tracked, Intuitive Surgical had the 25th highest net out-flow for the day. Intuitive Surgical traded up $9.62 for the day and closed at $488.10
- [By ]
And stocks are following suit. Intuitive Surgical (NASDAQ: ISRG) for example, has been on strong, steady climb for the better part of a year.
Top 10 Growth Stocks For 2019: TrueBlue Inc.(TBI)
Advisors' Opinion:- [By Logan Wallace]
Trueblue (NYSE: TBI) is one of 23 public companies in the “Help supply services” industry, but how does it contrast to its rivals? We will compare Trueblue to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, earnings and risk.
- [By Logan Wallace]
Media stories about Trueblue (NYSE:TBI) have trended somewhat positive on Monday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Trueblue earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the business services provider an impact score of 45.3296498009881 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
- [By Max Byerly]
Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Trueblue Inc (NYSE:TBI) by 18.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,550 shares of the business services provider’s stock after purchasing an additional 4,700 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Trueblue were worth $823,000 as of its most recent filing with the Securities & Exchange Commission.
- [By Logan Wallace]
Get a free copy of the Zacks research report on Trueblue (TBI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
ValuEngine downgraded shares of Trueblue (NYSE:TBI) from a hold rating to a sell rating in a report issued on Friday morning.
Several other research firms have also recently weighed in on TBI. Zacks Investment Research cut shares of Trueblue from a hold rating to a sell rating in a research report on Tuesday, February 12th. BMO Capital Markets decreased their price objective on shares of Trueblue from $26.00 to $24.00 and set a market perform rating for the company in a research report on Monday, February 11th. TheStreet cut shares of Trueblue from a b- rating to a c rating in a research report on Monday, December 31st. Finally, Credit Suisse Group decreased their price objective on shares of Trueblue from $31.00 to $25.00 and set a hold rating for the company in a research report on Tuesday, November 6th. Two equities research analysts have rated the stock with a sell rating and three have given a hold rating to the company. Trueblue presently has an average rating of Hold and a consensus price target of $26.00.
No comments:
Post a Comment